N-[3-amino-4-(2-carbamoyl-ethylamino)-phenyl]-N-methyl-benzamide | 658700-11-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[3-amino-4-(2-carbamoyl-ethylamino)-phenyl]-N-methyl-benzamide
• 英文别名: N-[3-amino-4-[(3-amino-3-oxopropyl)amino]phenyl]-N-methylbenzamide
• CAS: 658700-11-9
• 化学式: C₁₇H₂₀N₄O₂
• 分子量: 312.371
• InChiKey: IQOZLUMWRKFMBX-UHFFFAOYSA-N

物化性质

• 沸点：
  643.0±55.0 °C(Predicted)
• 密度：
  1.288±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  101
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-[3-amino-4-(2-carbamoyl-ethylamino)-phenyl]-N-methyl-benzamide 、 溴化氰 在 乙酸乙酯 、 碳酸氢钠 、 水 作用下， 以 乙醇 为溶剂， 反应 38.0h， 以to give 9.2 g (95%) of title compound as a crystalline solid的产率得到N-[2-amino-1-(3-amino-3-oxopropyl)-1H-benzimidazol-5-yl]-N-methylbenzamide
  参考文献：
  名称：

  Tec kinase inhibitors

  摘要：

  本发明公开了式(I)的化合物：其中Ar1、Ar2、R1、R2、R3、R4和Xa的定义如下。本发明的化合物抑制Itk激酶，因此可用于治疗涉及炎症、免疫紊乱和过敏症的疾病和病理条件。本发明还公开了制备这些化合物的方法和包含这些化合物的药物组合物。

  公开号：

  US20050209284A1
• 作为产物：
  描述：

  N-[4-(2-carbamoyl-ethylamino)-3-nitro-phenyl]-N-methyl-benzamide 在 钯 氢气 作用下， 以 甲醇 为溶剂， 反应 5.0h， 以providing N-[3-amino-4-(2-carbamoyl-ethylamino)-phenyl]-N-methyl-benzamide which的产率得到N-[3-amino-4-(2-carbamoyl-ethylamino)-phenyl]-N-methyl-benzamide
  参考文献：
  名称：

  Tec kinase inhibitors

  摘要：

  本发明公开了式(I)的化合物：其中Ar1、Ar2、R1、R2、R3、R4和Xa的定义如下。本发明的化合物抑制Itk激酶，因此可用于治疗涉及炎症、免疫紊乱和过敏症的疾病和病理条件。本发明还公开了制备这些化合物的方法和包含这些化合物的药物组合物。

  公开号：

  US20050209284A1

文献信息

• [EN] SUBSTITUTED BENZIMIDAZOLE COMPOUNDS<br/>[FR] COMPOSES BENZIMIDAZOLE SUBSTITUES
  申请人：BOEHRINGER INGELHEIM PHARMA

  公开号：WO2004014905A1

  公开（公告）日：2004-02-19

  Disclosed are substituted benzimidazole compounds of formula (I) wherein R1, R2, R3, R4 and Xa are defined herein. The compounds of the invention inhibit Itk kinase and are therefore useful for treating diseases and pathological conditions involving inflammation, immunological disorders and allergic disorders. Also disclosed are processes for preparing these compounds and the pharmaceutical compositions comprising these compounds.

  揭示了一种化学式（I）中的取代苯并咪唑化合物，其中R1、R2、R3、R4和Xa在此处定义。该发明的化合物抑制Itk激酶，因此可用于治疗涉及炎症、免疫紊乱和过敏性疾病的疾病和病理状况。还揭示了制备这些化合物的方法以及包含这些化合物的药物组合物。
• [EN] THIOPHENE -2- CARBOXYLIC ACID - (1H - BENZIMIDAZOL - 2 YL) - AMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE TEC KINASE ITK (INTERLEUKIN -2- INDUCIBLE T CELL KINASE) FOR THE TREATMENT OF INFLAMMATION, IMMUNOLOGICAL AND ALLERGIC DISORDERS<br/>[FR] DERIVES D'ACIDE THIOPHENE-2-CARBOXYLIQUE (1H-BENZIMIDAZOL-2 YL)-AMIDE ET COMPOSES ASSOCIES UTILISES COMME INHIBITEURS DE LA TEC KINASE ITK (KINASE DES LYMPHOCITES INDUCTIBLES PAR L'INTERLEUKINE -2) POUR TRAITER UNE INFLAMMATION ET DES TROUBLES IMMUNOLOGIQUES ET ALLERGIQUES
  申请人：BOEHRINGER INGELHEIM PHARMA

  公开号：WO2005079791A1

  公开（公告）日：2005-09-01

  Disclosed are compounds of formula (I): wherein Ar1, Ar2, R1, R2, R3, R4 and Xa are defined herein. The compounds of the invention inhibit Itk kinase and are therefore useful for treating diseases and pathological conditions involving inflammation, immunological disorders and allergic disorders. Also disclosed are processes for preparing these compounds and to pharmaceutical compositions comprising these compounds.

  揭示了式（I）的化合物：其中Ar1、Ar2、R1、R2、R3、R4和Xa在此定义。该发明的化合物抑制Itk激酶，因此对于治疗涉及炎症、免疫紊乱和过敏疾病的疾病和病理状况是有用的。还公开了制备这些化合物的方法以及包含这些化合物的药物组合物。
• [EN] NOVEL UREA DERIVATIVES AS TEC KINASE INHIBITORS AND USES THEREOF<br/>[FR] NOUVEAUX DÉRIVÉS D'URÉE EN TANT QU'INHIBITEURS DE KINASE TEC ET LEURS UTILISATIONS
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2013024427A1

  公开（公告）日：2013-02-21

  Provided are urea compounds of formula (I) as Tec kinase inhibitors, in particular ITK (interleukin-2 inducible tyrosine kinase) inhibitors. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders mediated by ITK.

  提供的是式（I）的尿素化合物，作为Tec激酶抑制剂，特别是ITK（白细胞介素-2诱导酪氨酸激酶）抑制剂。本文还提供了制备所述化合物的方法、用于合成的中间体、药物组合物以及治疗或预防由ITK介导的疾病、状况和/或紊乱的方法。
• Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug design
  作者：Brian N. Cook、Jörg Bentzien、Andre White、Peter A. Nemoto、Ji Wang、Chuk C. Man、Fariba Soleymanzadeh、Hnin Hnin Khine、Mohammed A. Kashem、Stanley Z. Kugler、John P. Wolak、Gregory P. Roth、Stéphane De Lombaert、Steven S. Pullen、Hidenori Takahashi

  DOI：10.1016/j.bmcl.2008.12.028

  日期：2009.2

  Interleukin-2 inducible T-cell kinase (ITK) is a member of the Tec kinase family and is involved with T-cell activation and proliferation. Due to its critical role in acting as a modulator of T-cells, ITK inhibitors could provide a novel route to anti-inflammatory therapy. This work describes the discovery of ITK inhibitors through structure-based design where high-resolution crystal structural information was used to optimize interactions within the kinase specificity pocket of the enzyme to improve both potency and selectivity. (C) 2009 Elsevier Ltd. All rights reserved.
• Discovery, SAR and X-ray structure of 1H-benzimidazole-5-carboxylic acid cyclohexyl-methyl-amides as inhibitors of inducible T-cell kinase (Itk)
  作者：Kevin J. Moriarty、Hidenori Takahashi、Steven S. Pullen、Hnin Hnin Khine、Rosemarie H. Sallati、Ernest L. Raymond、Joseph R. Woska、Deborah D. Jeanfavre、Gregory P. Roth、Michael P. Winters、Lei Qiao、Declan Ryan、Renee DesJarlais、Darius Robinson、Matthew Wilson、Mark Bobko、Brian N. Cook、Ho Yin Lo、Peter A. Nemoto、Mohammed A. Kashem、John P. Wolak、André White、Ronald L. Magolda、Bruce Tomczuk

  DOI：10.1016/j.bmcl.2008.09.015

  日期：2008.10

  A series of novel potent benzimidazole based inhibitors of interleukin-2 T-cell kinase (Itk) were prepared. In this report, we discuss the structure-activity relationship (SAR), selectivity, and cell-based activity for the series. We also discuss the SAR associated with an X-ray structure of one of the small-molecule inhibitors bound to ITK. (c) 2008 Elsevier Ltd. All rights reserved.